All News

Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

Ref: GlobeNewswire

Tags: Press Release Relief Therapeutics NeuroRx COVID-19 ARDS Clinical Research (R&D)RLF-100

Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine

Ref: GlobeNewswire

Tags: Press Release Satsuma Pharmaceuticals Migraine Clinical Research (R&D)STS101

argenx announces closing of global offering

Ref: GlobeNewswire

Tags: Press Release arGEN-X Corporate Affairs

Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

Ref: PR Newswire

Tags: Press Release Arena Pharmaceuticals Corporate Affairs

Kaleido Biosciences Announces Proposed Public Offering of Common Stock

Ref: GlobeNewswire

Tags: Press Release Kaleido Biosciences Corporate Affairs

BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants

Ref: GlobeNewswire

Tags: Press Release BioCryst Corporate Affairs

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

Ref: GlobeNewswire

Tags: Press Release Intellia Therapeutics Corporate Affairs

FDA alerts patients and health care professionals of Amneal and Impax Laboratories epinephrine auto-injector device malfunctions

Ref: FDA

Tags: Press Release Amneal Impax FDA Regulatory Affairs

Mark Genovese Joins Gilead to Lead Clinical Development of Company’s Inflammation Programs

Ref: Business Wire

Tags: People News Gilead Corporate Affairs

Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update

Ref: PR Newswire

Tags: Press Release Protalix Corporate Affairs